VRUS—I'm not following you on this. RG7128 showed excellent safety and efficiency in Genotypes 2&3 in phase-1 studies. What makes perfect sense?
RG7128 is badly suited for formulation in an all-in-one combination pill insofar as it requires a cumulative daily dose of 1,000-2,000 mg. It also requires BID administration, although this is probably a lesser drawback than the high dose.
Given that the geno-2/3 market is relatively small (compared to geno-1/4), Roche was already late in starting a phase-2b trial (compared to the geno-1/4 program), and the HCV market is moving toward all-oral regimens, an RG7128+interferon+ribavirin program for genotypes 2/3 is not especially compelling from a business standpoint, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.